stockportfolio.pro
Stocks / DVA vs IONS
DVA vs IONS
DaVita Inc. and Ionis Pharmaceuticals, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| DaVita Inc. (DVA) | Ionis Pharmaceuticals, Inc. (IONS) | |
|---|---|---|
| Market cap | $12.7B | $12.2B |
| Revenue (latest FY) | $13.64B | $943.71M |
| Net income (latest FY) | $746.80M | $-381.39M |
| Revenue growth (5y CAGR) | 3.4% | 5.3% |
| Net margin | 5.5% | -40.4% |
| Return on equity | -114.7% | -78.0% |
| P/E ratio | 19.1 | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 10 | 3 |
| Positive free cash flow | Yes | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open DVA — free Open IONS — freeFrequently asked questions
Which is bigger, DVA or IONS?
DaVita Inc. is larger by market capitalization — $12.7B versus $12.2B.
Which grows faster, DVA or IONS?
Over the last five fiscal years, Ionis Pharmaceuticals, Inc. grew revenue faster — 5.3%/yr versus 3.4%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.